Log In Sign up
The largest database of trusted experimental protocols

Irdye 680lt conjugated secondary antibody

Manufactured by LI COR
Visit Supplier
Sourced in United States

IRDye 680LT-conjugated secondary antibodies are fluorescent-labeled antibodies designed for use in Western blotting and other near-infrared fluorescence imaging applications. The IRDye 680LT dye provides a bright, stable fluorescent signal in the near-infrared region of the spectrum.

Automatically generated - may contain errors

Lab products found in correlation

Odyssey imager, by LI COR (3 mentions) Bcl xl, by Cell Signaling Technology (2 mentions) Gw501516, by GlaxoSmithKline (1 mentions) Tubulin, by Merck Group (1 mentions) Nf kb2 p100 p52, by Cell Signaling Technology (1 mentions) Gapdh, by Merck Group (1 mentions) Accuspin system histopaque 1077 tubes, by Merck Group (1 mentions) Anti eif4e, by Santa Cruz Biotechnology (1 mentions) Anti pdcd4, by Abcam (1 mentions) Anti actin, by Abcam (1 mentions) Cdc25b, by Cell Signaling Technology (1 mentions) Ccnd3, by Cell Signaling Technology (1 mentions) Imagequant software, by GE Healthcare (1 mentions) Labscan software, by GE Healthcare (1 mentions) Anti eif4a1, by Abcam (1 mentions) Pi3kca, by Cell Signaling Technology (1 mentions) Hnrnpa1, by Abcam (1 mentions) Imagescanner 3, by GE Healthcare (1 mentions) Odyssey system, by LI COR (1 mentions)

5 protocols using irdye 680lt conjugated secondary antibody

1

Regulation of PPAR Signaling in Inflammation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary antibodies used in this study: monoclonal anti-α-SMA, PCNA, GAPDH, polyclonal anti-PPARβ/δ, β-tubulin, TGase1, collagen type I and ALOX5AP (Santa Cruz, USA); polyclonal anti-Ly6C/Ly-6G (BioLegend, USA); polyclonal anti-vimentin and LRG1 (Abcam, USA). IRDye® 680LT conjugated secondary antibodies were from Li-Cor (Biosciences, USA); DyLight® conjugated secondary antibodies were from Vector Laboratories, USA. GW501516 (PPARβ/δ agonist; GW), GSK0660 (PPARβ/δ antagonist; GSK) and compound 10h (PPARβ/δ inverse agonist; 10h) were synthesized in-house.
Sng M.K., Chan J.S., Teo Z., Phua T., Tan E.H., Wee J.W., Koh N.J., Tan C.K., Chen J.P., Pal M., Tong B.M., Tnay Y.L., Ng X.R., Zhu P., Chiba S., Wang X., Wahli W, & Tan N.S. (2018). Selective deletion of PPARβ/δ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression. Cell Discovery, 4, 15.
+ Open protocol
+ Expand
2

Quantitative Protein Analysis by Western Blot

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Protein extraction and Western blot analyses with primary antibodies to pJNK, Mcl-1, XIAP, and GAPDH were done as previously described (28 (link)). A PARP-specific antibody (BD Pharmingen) was also included. An Odyssey Imager (LI-COR Biosciences) was used to quantify binding of IRDye 680LT-conjugated secondary antibodies (LI-COR Biosciences).
Holkova B., Kmieciak M., Perkins E.B., Bose P., Baz R.C., Roodman G.D., Stuart R.K., Ramakrishnan V., Wan W., Peer C.J., Dawson J., Kang L., Honeycutt C., Tombes M.B., Shrader E., Weir-Wiggins C., Wellons M., Sankala H., Hogan K.T., Colevas A.D., Doyle L.A., Figg W.D., Coppola D., Roberts J.D., Sullivan D, & Grant S. (2014). Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Non-Hybrid “(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(22), 5652-5662.
+ Open protocol
+ Expand
3

Profiling Molecular Changes in CLL

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Triplicate samples of peripheral blood (5 to 6 mL) were obtained before (pre-treatment) and 20 to 24 hours after cycle 1 day 1 of study treatment (post-treatment). Samples were collected only from patients with CLL with WBC greater than or equal to 15,000 and 70% lymphocytes to avoid problems with interpretation due to cellular heterogeneity. Sample collection was optional for patients. PBMC were isolated by Ficoll gradient according to the manufacturer’s instructions, and protein extraction and Western blot analyses were performed as previously described [25 (link)]. Immunoblots were probed with the following primary antibodies: Bcl-XL (Cell Signaling), Bim (Cell Signaling), GAPDH (Sigma), NFkB2 p100/p52 (Cell Signaling), p84 (ThermoFisher Scientific), NFkB p65/RelA (Millipore), tubulin (Sigma), and XIAP (Cell Signaling). Prior to Western blot analysis of RelA, the nuclear fraction was isolated according to Suzuki et al [26 (link)]. An Odyssey Imager (LI-COR Biosciences) was used to quantify binding of IRDye 680LT-conjugated secondary antibodies (LI-COR Biosciences).
Holkova B., Yazbeck V., Kmieciak M., Bose P., Ma S., Kimball A., Tombes M.B., Shrader E., Wan W., Weir-Wiggins C., Singh A., Hogan K.T., Conine S., Sankala H., Roberts J.D., Shea T.C, & Grant S. (2017). A Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma. Leukemia & lymphoma, 58(6), 1349-1357.
+ Open protocol
+ Expand
4

Leukemic Blast Protein Profiling

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Research samples were collected from consenting patients with ≥ 65% leukemic blasts in blood or bone marrow aspirate. Both prior to and 24 hours (± 5 hours) following treatment, triplicate peripheral blood samples or a single bone marrow aspirate were obtained. Whole blood (5-6 mL) was collected into tubes containing either sodium heparin or EDTA. Bone marrow aspirate (10 mL) was collected in a heparinized syringe. Peripheral blood mononuclear cells were isolated using Accuspin System-Histopaque-1077 tubes (Sigma) according to the manufacturer’s instructions, and the cells were subsequently stored at −80°C.
Protein extraction and Western blot analysis was done as previously described [19 (link)]. Antibodies to the following proteins were used: Bcl-XL (Cell Signaling), Bim (Calbiochem), NF-kB p65/RelA (Chemicon), and XIAP (BD Biosciences). Western blot analysis of p65/RelA was performed on a nuclear fraction isolated according to Suzuki et al. [20 (link)]. An Odyssey Imager (LI-COR Biosciences) was used to quantify binding of IRDye 680LT-conjugated secondary antibody (LI-COR Biosciences).
Holkova B., Shafer D., Yazbeck V., Dave S., Bose P., Tombes M.B., Shrader E., Wan W., Bandyopadhyay D., Weir C., Collins E.B., Garnett A., Kmieciak M., Roberts J.D., Garcia-Manero G, & Grant S. (2020). Phase 1 Study of Belinostat (PXD-101) and Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory Acute Leukemia and Myelodysplastic Syndrome. Leukemia & lymphoma, 62(5), 1187-1194.
+ Open protocol
+ Expand
5

Comprehensive Protein Quantification Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blots were probed using the following primary antibodies: anti-eIF4E (Santa Cruz Biotechnology, Santa Cruz, CA, USA; sc-9976), anti-eIF4A1 (Abcam, Cambridge, UK; ab31217), anti-eIF4B (Epitomics, Burlingame, CA, USA; 2232-1), anti-PDCD4 (Abcam, ab80590), anti-actin (Abcam, ab6276), CCND3 (Cell Signaling, Beverly, MA, USA; 2936), PI3KCA (Cell Signaling, 4249), CDC25B (Cell Signaling, 9525), NPM1 (Cell Signaling, 3542), GNAS (Abcam, ab83735), RPL27A (Abcam, ab74731), hnRNPA1 (Abcam, ab4791) and RPS25 (GeneTex, Irvine, CA, USA; 101526). Suitable secondary antibodies were used for chemiluminescence detection. Samples were analyzed from at least two independent experiments.
Films were scanned on an ImageScanner III using LabScan software (GE Healthcare) and proteins were quantified using ImageQuant software (GE Healthcare), or for Licor analysis, IRDye 680LT-conjugated secondary antibody (LI-COR Biosciences, Lincoln, NE, USA) was used, followed by scanning on the Odyssey system (LI-COR Biosciences).
Modelska A., Turro E., Russell R., Beaton J., Sbarrato T., Spriggs K., Miller J., Gräf S., Provenzano E., Blows F., Pharoah P., Caldas C, & Le Quesne J. (2015). The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape. Cell Death & Disease, 6(1), e1603-.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!